Amgen’s Prolia Gets FDA Boxed Warning for Risk of Severe Hypocalcemia

The US Food and Drug Administration (FDA) has added a boxed warning to the safety information of Amgen’s osteoporosis drug Prolia (denosumab) for the increased risk of severe hypocalcemia in patients with advanced chronic kidney disease (CKD).